Market revenue in 2023 | USD 11,720.6 million |
Market revenue in 2030 | USD 18,683.5 million |
Growth rate | 6.9% (CAGR from 2023 to 2030) |
Largest segment | Insulin delivery devices |
Fastest growing segment | Insulin Delivery Devices |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Blood Glucose Monitoring (BGM) Devices, Insulin Delivery Devices |
Key market players worldwide | Medtronic PLC, Abbott Laboratories, Roche Holding AG, Bayer AG, Johnson & Johnson, B. Braun, DexCom Inc, Insulet Corp, Ypsomed Holding AG, Sanofi SA, Novo Nordisk A/S ADR, Arkray |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to diabetes devices market will help companies and investors design strategic landscapes.
Insulin delivery devices was the largest segment with a revenue share of 54.18% in 2023. Horizon Databook has segmented the North America diabetes devices market based on blood glucose monitoring (bgm) devices, insulin delivery devices covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated the diabetes devices market in 2022 with the largest market share and is expected to maintain its dominance during the forecast period. Major factors contributing to the growth of this region include increasing geriatric population, growing burden of diabetes due to lifestyle changes, increasing prevalence of obesity, and high cost of treatment.
Some of the market leaders, such as Abbott, Medtronic, Dexcom, and Insulet Corporation, have their operational headquarters in this region, which is contributing to the market growth. According to American Diabetes Association, in 2021, the North America and Caribbean Region had the highest expenditure for diabetes of around USD 415 billion, which accounted for around 43% of global expenditure.
Furthermore, the adoption of smart diabetes devices and technologically advanced devices such as the use of Artificial Intelligence (AI) & data analytics are driving the market. According to the International Diabetes Federation, one in eight adults suffers from impaired blood glucose tolerance. This ratio is expected to increase further during the forecast period.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America diabetes devices market , including forecasts for subscribers. This continent databook contains high-level insights into North America diabetes devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account